Alkermes (ALKS) Competitors $29.71 -0.26 (-0.87%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ALKS vs. UTHR, NBIX, INCY, BMRN, EXAS, EXEL, RGEN, MDGL, HALO, and IONSShould you be buying Alkermes stock or one of its competitors? The main competitors of Alkermes include United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Exelixis (EXEL), Repligen (RGEN), Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), and Ionis Pharmaceuticals (IONS). These companies are all part of the "biotechnology" industry. Alkermes vs. United Therapeutics Neurocrine Biosciences Incyte BioMarin Pharmaceutical Exact Sciences Exelixis Repligen Madrigal Pharmaceuticals Halozyme Therapeutics Ionis Pharmaceuticals Alkermes (NASDAQ:ALKS) and United Therapeutics (NASDAQ:UTHR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations, community ranking and institutional ownership. Which has preferable valuation & earnings, ALKS or UTHR? United Therapeutics has higher revenue and earnings than Alkermes. Alkermes is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlkermes$1.51B3.19$355.76M$1.9515.24United Therapeutics$2.76B5.82$984.80M$22.7715.79 Does the media prefer ALKS or UTHR? In the previous week, United Therapeutics had 10 more articles in the media than Alkermes. MarketBeat recorded 15 mentions for United Therapeutics and 5 mentions for Alkermes. Alkermes' average media sentiment score of 1.33 beat United Therapeutics' score of 1.07 indicating that Alkermes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive United Therapeutics 10 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Does the MarketBeat Community prefer ALKS or UTHR? Alkermes received 107 more outperform votes than United Therapeutics when rated by MarketBeat users. Likewise, 70.51% of users gave Alkermes an outperform vote while only 62.34% of users gave United Therapeutics an outperform vote. CompanyUnderperformOutperformAlkermesOutperform Votes69870.51% Underperform Votes29229.49% United TherapeuticsOutperform Votes59162.34% Underperform Votes35737.66% Is ALKS or UTHR more profitable? United Therapeutics has a net margin of 40.31% compared to Alkermes' net margin of 22.15%. Alkermes' return on equity of 24.92% beat United Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Alkermes22.15% 24.92% 14.55% United Therapeutics 40.31%19.22%16.15% Do institutionals & insiders hold more shares of ALKS or UTHR? 95.2% of Alkermes shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 4.9% of Alkermes shares are owned by insiders. Comparatively, 11.9% of United Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts rate ALKS or UTHR? Alkermes currently has a consensus price target of $35.42, suggesting a potential upside of 19.21%. United Therapeutics has a consensus price target of $370.86, suggesting a potential upside of 3.14%. Given Alkermes' higher possible upside, equities analysts clearly believe Alkermes is more favorable than United Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alkermes 1 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.58United Therapeutics 1 Sell rating(s) 2 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.73 Which has more volatility & risk, ALKS or UTHR? Alkermes has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500. SummaryUnited Therapeutics beats Alkermes on 12 of the 18 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Alkermes News Delivered to You Automatically Sign up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALKS vs. The Competition Export to ExcelMetricAlkermesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.81B$6.57B$5.06B$9.08BDividend YieldN/A3.11%4.84%4.21%P/E Ratio15.2410.55102.6717.15Price / Sales3.19195.041,121.74116.80Price / Cash13.6357.1641.3037.88Price / Book4.125.104.744.78Net Income$355.76M$151.51M$119.11M$225.60M7 Day Performance-2.62%-2.13%-1.86%-1.21%1 Month Performance6.91%-3.13%11.37%3.09%1 Year Performance7.84%11.54%30.22%16.48% Alkermes Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALKSAlkermes4.6624 of 5 stars$29.71-0.9%$35.42+19.2%+9.3%$4.81B$1.51B15.242,100Positive NewsHigh Trading VolumeUTHRUnited Therapeutics4.708 of 5 stars$370.95+2.5%$370.860.0%+59.5%$16.56B$2.76B16.221,168Analyst DowngradeInsider TradePositive NewsNBIXNeurocrine Biosciences4.8249 of 5 stars$134.00+5.8%$165.00+23.1%+12.6%$13.57B$2.24B35.791,400Analyst ForecastInsider TradePositive NewsINCYIncyte4.7042 of 5 stars$70.38+2.7%$76.13+8.2%+13.3%$13.56B$4.08B489.642,524Analyst ForecastBMRNBioMarin Pharmaceutical4.9838 of 5 stars$66.07+0.1%$94.20+42.6%-29.1%$12.59B$2.75B39.533,401Positive NewsEXASExact Sciences4.4854 of 5 stars$60.48-1.3%$72.94+20.6%-11.7%$11.19B$2.50B-52.356,600EXELExelixis4.5077 of 5 stars$36.01+2.8%$31.47-12.6%+43.4%$10.28B$2.08B22.461,310Analyst DowngradeAnalyst RevisionRGENRepligen4.0971 of 5 stars$160.24+2.4%$190.25+18.7%-19.7%$8.98B$639.92M-422.731,783Analyst ForecastPositive NewsMDGLMadrigal Pharmaceuticals4.2396 of 5 stars$310.87+2.1%$347.33+11.7%+39.5%$6.78BN/A-12.1490Positive NewsHALOHalozyme Therapeutics4.9948 of 5 stars$48.39+0.8%$61.11+26.3%+29.1%$6.16B$947.36M15.98390Analyst ForecastPositive NewsIONSIonis Pharmaceuticals4.4165 of 5 stars$38.46+5.1%$60.65+57.7%-26.3%$6.07B$803.07M-15.00800Analyst ForecastShort Interest ↓Analyst RevisionNews CoveragePositive News Related Companies and Tools Related Companies United Therapeutics Alternatives Neurocrine Biosciences Alternatives Incyte Alternatives BioMarin Pharmaceutical Alternatives Exact Sciences Alternatives Exelixis Alternatives Repligen Alternatives Madrigal Pharmaceuticals Alternatives Halozyme Therapeutics Alternatives Ionis Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALKS) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alkermes plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Alkermes With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALKS Stock Alerts